Nov 24, 1989 - Wayne Ghesquiere, Jean H. Gillies, Brian Inglis, Daniel. Levine, Justin Martin, Leonard Peress, Irving Rother, M. Lynn Russell and Martin L.
EPIDEMIOLOGIC REPORT * ETUDE EPIDEMIOLOGIQUE
Eosinophilia - myalgia syndrome A t the end of October 1989 health authorities in the United States began receiving reports of patients with eosinophilia and severe myalgia who had been receiving oral preparations of L-tryptophan.' Soon after public announcement similar cases were reported. Case-control studies established a significant association between the use of products containing L-tryptophan and the development of eosinophilia-myalgia syndrome (EMS).2 For surveillance purposes the US Centers for Disease Control (CDC), Atlanta, defined EMS as an illness characterized by the following: (a) an eosinophil count of at least 1.0 x 109/L, (b) generalized myalgia at some point during the course of the illness that affects the patient's usual daily activities and (c) absence of any infection or neoplasm that could account for either of these characteristics. The CDC has stated that automated procedures for leukocyte differential counts can yield a falsenormal eosinophil count. If this occurs among patients who are receiving the drug and whose symptoms resemble EMS the eosinophil count should be redone by means of a nonautomated procedure. As of Apr. 27, 1990, 1479 cases of EMS had been reported to the CDC. Of the patients who had been taking products containing L-tryptophan before the onset of illness 21 died. Women accounted for over 80% of the EMS cases. The median daily dose of L-tryptophan was 1.5 g, although at least in one case it was below 0.1 g. In nearly 90% of the cases EMS developed after July 1989. A contaminant is currently believed to be involved, but none has yet been unequivocally identified (CDC: unpublished data, 1990). On Nov. 24, 1989, the Health Protection Branch
of the Department of National Health and Welfare, Ottawa, issued a warning to consumers not to use dietary supplements containing L-tryptophan. As of Apr. 30, 1990, 10 confirmed cases of EMS have been reported to the Laboratory Centre for Disease Control, Ottawa (Table 1). Other possible cases are under investigation. All 10 cases have been linked to the use of dietary supplements and other products containing the drug. All but two involved women. Eight patients had purchased the dietary supplements in the United States. One other patient had bought the drug from a Canadian pharmacy that had made tablets from bulk material, and another had obtained nonprescription dietary supplements manufactured in the United States and distributed illegally in Canada. Since 1985 in Canada products containing L-tryptophan alone must be prescribed by a physician. Tryptan (ICN Canada Ltd., Montreal) is the only such product legally available in Canada. To date, no cases of EMS have been reported among patients receiving this product. In the United States L-tryptophan as a singleingredient product was readily available over the counter until Mar. 22, 1990. This probably explains the discrepancy in case occurrence between the two countries. However, officials from the Department of National Health and Welfare believe that not all cases in Canada have been recognized yet. Greater public awareness and a higher degree of suspicion among physicians in the United States may also explain the higher numbers of cases reported there. Laboratory and epidemiologic investigations of EMS are under way in Canada and the United
Based on material previously reported in Canada Diseases Weekly Report (a publication of the Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control, Department of National Health and Welfare, Tunney's Pasture, Ottawa, Ont. KIA OL2) by Kathryn Wilkins, MSc, and Donald Wigle, MD, Bureau of Chronic Disease Epidemiology, Laboratory Centre for Disease Control (1989; 15: 245-246, 251-252, and 1990; 16: 28-30, 69-70). Publication in CMAJ is with permission of the authors and the bureau. Reprint requests to: Kathryn Wilkins, Bureau of Chronic Disease Epidemiology, Laboratory Centre for Disease Control, Tunney's Pasture, Ottawa, Ont. KIA OL2 CAN MED ASSOC J 1990; 142 (I 1)
1265
Yable ! Characteristics of 10 cases of eosinophilia-myalgia
syndrome in Canada as of Apr 30
990
Maximum ase
O
eosinophil
Patient s age yr/sex
Location
4 1'/F 46/F
Ottawia
2)4
Torontcw
4 ,I
Daily dose of 1 09I/LL -tryptophanr.
rount
Oinset of-
Source
vymptom-'.- If drug
Apr 1,989 1Njilv 989c
'sui
eatu;.'.
a!
,anada 5-t.
U,JSA
4sperguilus-pou';-v-
USA
filtratec :dema. adenor&rma d. sever-...
d puI mo'u
38 F
Abbotsfor. BC
46/F
Victoria.
-7
,
'Ict 1 989 ::.
..) .a
I
T oronto Sylvan Lake Alta
4*8
:O/M
St. Catharines Ont
2*-
39iF
Vancouver
281M
Victoria
f61 / F
39/.F
I..
L..indsay. COn t
N ov 1989 USA Sept 1989 LSA
J. -n ;.I
U
vspnea anc .e-aKness
Nov. 1989
IDec 1989
phocytic .As. *SA ISAJSA edema anr .aigia aftr ern.:,ise
Urmnowrl
.Unknowr
Nov I 989
;SA
Vl a r
USA
.2
99u
NOV.- ' 989
e::lar\,
ii 1r.i
.-.Qtr0de[ mTa yalgia afte zxercise aanadaaPuimonary nfiltrae -nd eosinophifl. oerivascula * }Irove n rrer!
States. Physicians are urged to report any cases that Wayne Ghesquiere, Jean H. Gillies, Brian Inglis, Daniel meet the entry criteria to Dr. Donald Wigle, acting Levine, Justin Martin, Leonard Peress, Irving Rother, M. director, Bureau of Chronic Disease Epidemiology, Lynn Russell and Martin L. Samosh. Laboratory Centre for Disease Control, Department of National Health and Welfare, Ottawa, Ont. References KIA OL2; (613) 957-0329; FAX (613) 952-7009. The authors gratefully acknowledge the CMA for alerting physicians regarding EMS and the following physicians who reported cases: Drs. Malcolm Brigden, Donald Cook,
1. Eosinophilia-myalgia syndrome New Mexico. MMAlWXR 1989; 38: 765-767 2. Eosinophilia-myalgia syndrome and L-tryptophan-containing products - New Mexico, Minnesota, Oregon, and New York, 1989. Ibid: 785-788
The capacity of man
We are tending to become a standardized country, and it is perhaps on standardization that industrial progress is founded. But standardization of our educational systems is apt to stamp out individualism and defeat the very ends of education by levelling the product down rather than up. The qualities that really count in this world are quite beyond pigeonholing, quite beyond measurement by scales, tape, or mental tests, quite beyond rating by any known system of examination, all of which fail in giving us an estimate ofthat most precious ofall qualities, personality. The capacity of the man himself is only revealed when, under stress and responsibility, he breaks through his educational shell, and he may then be a splendid surprise to himselfno less than to his teachers. Harvey Cushing (1869-1939)
1266
CAN MED ASSOCJ 1990;
142(11)
